ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells
Conclusions:
Receptor sialylation by ST6Gal-I confers a survival advantage for tumor cells in the presence of cisplatin. These collective findings support a role for ST6Gal-I in chemoresistance and highlight ST6Gal-I as a potential therapeutic target for platinum resistant tumors.
Source: Journal of Ovarian Research - Category: Cancer & Oncology Authors: Matthew SchultzAmanda SwindallJohn WrightElizabeth SztulCharles LandenSusan Bellis Source Type: research